For providers
Clinical evidence

Rigorous, independent testing. Consistent results.

The Oncotype DX Breast Recurrence Score® test is validated to predict the likelihood of chemotherapy benefit in patients with node-negative or node-positive HR+, HER2- invasive breast cancer.1,2
Two Exact Sciences technicians working in a lab.

Level 1 evidence

The Oncotype DX Breast Recurrence Score test is the only test that provides level 1 evidence for prognosis of distant recurrence risk and prediction of chemotherapy benefit in patients with early-stage, HR+/HER2- invasive breast cancer, regardless of nodal status.1-5

Clinical validation studies

TAILORx trial

The Trial Assigning Individualized Options for Treatment (Rx), TAILORx, is the largest randomized, prospective, phase 3 trial assessing the ability of multi-gene assays to help inform adjuvant treatment strategies for women with early-stage breast cancer.6-11

Over 10,000 patients with node-negative (N0) disease across 7 countries around the world6,7
Demonstrated that the majority of patients with N0 disease may be able to safely forgo adjuvant chemotherapy6

RxPONDER trial

A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer, RxPONDER, expands the groundbreaking benefits to node-positive patients.12

Over 5,000 patients with node-positive (N1) disease
Demonstrated that the majority of postmenopausal patients with N1 breast cancer may be able to safely omit adjuvant chemotherapy from their treatment plan

SEER registry analysis

Long-term Surveillance, Epidemiology, and End Results (SEER)13

Over 6,000 patients
Demonstrated that the Oncotype DX Breast Recurrence Score test is prognostic for breast cancer-specific mortality in patients with invasive ductal carcinoma and invasive lobular breast cancer
A doctor seated at a desk looking at his laptop.

Ordering a test for your patients is fast and easy

Order tests, access results, and receive updates through our Provider Hub.

Have questions?

Call us at 1 866-662-6897.